Liquid biopsies are being widely studied as a minimally-invasive means for early detection of cancer, monitoring of disease progression, and guiding treatment decisions. However, recent studies in JAMA Oncology reported the discordance between circulating tumor DNA (ctDNA) assay results from commercial platforms such as Guardant Health and PGD, raising questions and concerns regarding the performance...